RxDoctor Payments Data

Kimberley Drayton, MD

Family Medicine · Pawleys Island, SCNPI 1386767226

Payments from drug & device makers

$6,426in general payments, 2019–2025

Across 390 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$736
  • AstraZeneca$550
  • Amgen$397
  • GSK$376
  • Merck$326
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,426 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$35,675
Medicare patients
445
Services billed
4,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$139,919
EliquisApixaban100$133,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$56,418
XifaxanRifaximin11$41,922
JardianceEmpagliflozin28$40,503
JanuviaSitagliptin Phosphate35$37,827
RybelsusSemaglutide23$31,972
XareltoRivaroxaban27$27,435
FarxigaDapagliflozin Propanediol33$26,151
MounjaroTirzepatide19$19,608
LinzessLinaclotide19$15,660
TrulicityDulaglutide14$13,946
Repatha PushtronexEvolocumab14$12,622
Breo ElliptaFluticasone/Vilanterol23$10,700
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$10,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,192$171,891134 claims
PfizerEliquis$279$133,430100 claims
GSKTrelegy Ellipta, Breo Ellipta$376$67,11977 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$18$41,92211 claims
Boehringer IngelheimJardiance$13$40,50328 claims
MerckJanuvia$326$37,82735 claims
Lilly USA, LLCMounjaro, Trulicity$148$33,55433 claims
Johnson & JohnsonXarelto$191$27,43527 claims
AstraZenecaFarxiga$550$26,15133 claims
AbbVieLinzess, Synthroid$736$22,012120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Pawleys Island

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →